An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
The heart is capable of terminating arrhythmias itself after local gene therapy, potentially avoiding the need for patients to undergo painful electric shocks, according to a proof-of-concept study presented today at EHRA 2018, a European Society of Cardiology congress.
Patients with atrial fibrillation could reduce the risk of dementia by taking stroke prevention medications, according to recommendations published online today in EP Europace, a European Society of Cardiology journal, and presented at EHRA 2018.
In the event of a cardiorespiratory arrest, two actions are crucial for the patient's survival: cardiopulmonary resuscitation and defibrillation.
Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, enrolled and treated the first patient in its SHINE clinical study in Europe.
Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of heart arrhythmias, has completed patient enrollment in its U.S. Investigational Device Exemption study of the THERMOCOOL SMARTTOUCH SF Catheter.
To prevent cardiac death, people with certain cardiac disorders are implanted with electronic devices designed to automatically stimulate the heartbeat or counteract serious arrhythmia if necessary.
Wearing a lightweight vest equipped with a cardioverter defibrillator that detects abnormal heart rhythms in addition to taking recommended medications is associated with a reduction in the likelihood of dying during the first 90 days following a heart attack in people whose heart function was also impaired, according to a study presented at the American College of Cardiology's 67th Annual Scientific Session.
Researchers in the UPV/EHU's Signal and Communications Group in collaboration with researchers in the Oregon Health & Science University have developed an algorithm to guide an effective cardiopulmonary resuscitation maneuver.
Peter Ruben and his team of researchers have spent years studying why seemingly healthy patients with inherited cardiac arrhythmias can sometimes suddenly die during exercise.
Football players show structural changes in the heart and face an elevated risk of heart rhythm disorders later in life, according to research presented at the American College of Cardiology's 67th Annual Scientific Session.
Johns Hopkins researchers report successful use of heart imaging to predict the benefit or futility of catheter ablation, an increasingly popular way to treat atrial fibrillation, a common heart rhythm disorder.
Atrial fibrillation (AF) is the most prevalent sustained cardiac arrhythmia, and its prevalence is projected to rise continuously over the next few decades because of an aging population.
Atrial fibrillation (AF) can often be asymptomatic, leading to difficulties in diagnosis and untreated risks for morbidity and mortality.
The largest global clinical study on the best-possible therapy for patients with atrial fibrillation at high risk of having a stroke and at increased risk of bleeding is starting at the German Centre for Cardiovascular Research.
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery from heart attack injury.
With a mortality rate estimated at 10%, the life-threatening condition known as thyroid storm (TS) demands rapid diagnosis and treatment and can benefit from new evidence-based guidelines for TS developed by researchers in Japan.
The proteasome inhibitor carfilzomib has taken on an increasing role in the treatment of multiple myeloma, but new research from the Abramson Cancer Center of the University of Pennsylvania shows the therapy comes with the risk of cardiovascular problems in a higher than expected percentage of patients.
Radiation therapy often is used to treat cancer patients. Now, doctors at Washington University School of Medicine in St. Louis have shown that radiation therapy - aimed directly at the heart -; can be used to treat patients with a life-threatening heart rhythm.
Some heart disease patients face a higher risk of sudden cardiac death, which can happen when an arrhythmia -- an irregular heartbeat-- disrupts the normal electrical activity in the heart and causes the organ to stop pumping.
A groundbreaking Loyola Medicine study suggests that a simple 15-minute electrocardiogram could help a physician determine whether a patient has major depression or bipolar disorder.